US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Cingulate Inc. - Warrants
(NQ:
CINGW
)
0.0051
UNCHANGED
Delayed Quote
Updated: 11:28 AM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cingulate Inc. - Warrants
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
September 05, 2023
Data Accepted as Finalist for First Annual Poster Awards
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 14, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
July 11, 2023
Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
June 29, 2023
Announcement Confirms Cingulate on Track with Development and Regulatory Milestones
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 08, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate to Present at 13th Annual LD Micro Invitational
May 25, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate, Indegene to Participate in Benzinga All Live Access Event
May 12, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
May 10, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
May 03, 2023
Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial Program
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate to Participate in Benzinga All Live Access Event
April 14, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 04, 2023
From
Cingulate Inc.
Via
GlobeNewswire
